Zobrazeno 1 - 10
of 1 103
pro vyhledávání: '"Diffuse large b-cell lymphoma (DLBCL)"'
Autor:
WANG Boen, CHEN Siyuan, SHI Qing, ZHANG Muchen, YI Hongmei, DONG Lei, WANG Li, CHENG Shu, XU Pengpeng, ZHAO Weili
Publikováno v:
Shanghai Jiaotong Daxue xuebao. Yixue ban, Vol 44, Iss 9, Pp 1162-1168 (2024)
Objective·To analyze the clinicopathologic characteristics of patients with kidney-involved diffuse large B-cell lymphoma (DLBCL), including clinical characteristics, pathological characteristics, gene mutation profiles, and prognostic factors.Metho
Externí odkaz:
https://doaj.org/article/ff1996797fef49e89966ce3ece7213f2
Autor:
Sylvia Zöphel, Nadja Küchler, Johanna Jansky, Cora Hoxha, Gertrud Schäfer, Julius J. Weise, Joanne Vialle, Lea Kaschek, Gebhard Stopper, Hermann Eichler, Daniela Yildiz, Alina Moter, Philipp Wendel, Evelyn Ullrich, Claudia Schormann, Torben Rixecker, Onur Cetin, Frank Neumann, Patrick Orth, Moritz Bewarder, Markus Hoth, Lorenz Thurner, Eva C. Schwarz
Publikováno v:
Molecular Cancer, Vol 23, Iss 1, Pp 1-9 (2024)
Abstract Assessing the prognosis of patients with aggressive non-Hodgkin B cell lymphoma mainly relies on a clinical risk score (IPI). Standard first-line therapies are based on a chemo-immunotherapy with rituximab, which mediates CD16-dependent anti
Externí odkaz:
https://doaj.org/article/c26da19e6df140a2bd9fa86950fc9b73
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Primary uterine non-Hodgkin lymphoma (NHL) is rarely reported, as its incidence is extremely low. We describe a 72 year old patient with primary uterine non-Hodgkin’s lymphoma stage IV, diffuse B-cell large cells, who responded well to cytotoxic ch
Externí odkaz:
https://doaj.org/article/abf517cba8a546c7b86a713ce9a5a53d
Autor:
Wenke Wu, Lei Miao, Lidong Zhao, Yuanxin Zhu, Jianping Mao, Zhimei Cai, Yajun Ji, Lei Wang, Ying Wang, Tao Jia
Publikováno v:
Hematology, Vol 29, Iss 1 (2024)
Objective To investigate the prognostic value of lactate dehydrogenase (LDH), serum albumin (ALB) and the lactate dehydrogenase/albumin ratio (LAR) in diffuse large B-cell lymphoma (DLBCL) before primary treatment.Methods The clinical data of 212 pri
Externí odkaz:
https://doaj.org/article/c4412c04fb9f4f55aaf31e5389499b97
Publikováno v:
Cancer Medicine, Vol 13, Iss 22, Pp n/a-n/a (2024)
ABSTRACT Background The objective of this study was to investigate the expression levels and biological significance of CKS2 in Burkitt cell lymphoma (BL) and diffuse large B‐cell lymphoma (DLBCL). Additionally, the potential synergistic anti‐tum
Externí odkaz:
https://doaj.org/article/06176a24b088472daef85902385f475d
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-9 (2024)
Abstract Emerging evidence shows that FAT atypical cadherin 1 (FAT1) mutations occur in lymphoma and are associated with poorer overall survival. Considering that diffuse large B cell lymphoma (DLBCL) is the category of lymphoma with the highest inci
Externí odkaz:
https://doaj.org/article/72c3a5788cf044f098d6751f5970792a
Autor:
Jingjing Ma, Zhiguang Lin, Yaqi Zhang, Yun Ding, Qiming Tang, Yufeng Qian, Bo Jin, Ruben Y. Luo, Wei-Li Liao, Sheeno Thyparambil, Zhi Han, C. James Chou, James Schilling, Qing Li, Mengxue Zhang, Yunan Lin, Yan Ma, Karl G. Sylvester, Seema Nagpal, Doff B. McElhinney, Xuefeng B. Ling, Bobin Chen
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
IntroductionPrimary central nervous system lymphoma (PCNSL) is a rare type of non-Hodgkin’s lymphoma that affects brain parenchyma, eyes, cerebrospinal fluid, and spinal cord. Diagnosing PCNSL can be challenging because imaging studies often show s
Externí odkaz:
https://doaj.org/article/dbd73c16b6144b0ab5b436e20370a0da
Autor:
Dimitris Tatsis, Athena Niakou, Konstantinos Paraskevopoulos, Stavroula Papadopoulou, Konstantinos Vahtsevanos
Publikováno v:
Hematology Reports, Vol 16, Iss 2, Pp 260-269 (2024)
Objectives: The aim of this review is to focus on the possibility of patients with squamous cell carcinoma to develop a second primary disease such as DLBCL, perhaps because of the irradiation of the head and neck area. Materials and methods: A case
Externí odkaz:
https://doaj.org/article/045ca2fe67fb496da89097391a13d3ce
Autor:
Divya Shanthi, Sathiya Vinotha
Publikováno v:
National Board of Examinations Journal of Medical Sciences, Vol Volume 2, Iss 3, Pp 256-263 (2024)
A novel antibody-drug conjugate (ADC), Polatuzumab vedotin has emerged as a promising player in the oncology field. This comprehensive review aims to elucidate the intricate details of Polatuzumab vedotin, encompassing its molecular structure, mechan
Externí odkaz:
https://doaj.org/article/c3c58ad332394996ab8bc3db1750ea73
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Chimeric antigen receptor (CAR) T-cell therapy is a revolutionary approach in the treatment of lymphoma. This review article provides an overview of the four FDA-approved CAR T-cell products for aggressive B-cell lymphoma, including diffuse large B-c
Externí odkaz:
https://doaj.org/article/bacde77b5e434402aa3b72d843d89947